Gen-Probe's Michael Watts sees five potential new product launches as delivering top-line growth next year.
Worries about the FDA's ruling on the relative safety of menthol cigarettes have left Lorillard's bonds looking attractively priced according to Morningstar's Dave Sekera.
Aptar COO Steve Hagge on how the firm's close client relationships and FDA-approved dispensers give the firm an advantage in consumer packaging.
News this week showed market players paying up for media assets, paying out for tax relief, and more.
Good day, ladies and gentlemen, and welcome to Isis Pharmaceuticals' Second Quarter Financial Results Conference Call. Leading the call today from Isis is Dr. Stanley Crook, Isis's Chairman and Chief Executive Officer. Dr. Crook, please begin.
©2012 Morningstar Advisor. All right reserved.